---
layout: default
title: Acacia Amaranthus Hybridus Leaf Amaranthus Tubercu
parent: 僅模型預測 (L5)
nav_order: 53
evidence_level: L5
indication_count: 0
---

# Acacia Amaranthus Hybridus Leaf Amaranthus Tubercu
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Allergen Corticotropin Complex: Allergy Diagnostic Panel — No Repurposing Prediction Available

## One-Sentence Summary

This product is a complex multi-component allergen mixture containing 30 biological and botanical constituents — including tree/weed/grass pollens, animal-derived extracts, CORTICOTROPIN (ACTH), and HISTAMINE DIHYDROCHLORIDE — consistent with an allergy skin-testing panel used for diagnosing allergic sensitivities.
The TxGNN model did not generate any repurposing predictions for this candidate, and no predicted new indication is available.
There is therefore **no evidence to evaluate** in the standard drug repurposing framework at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not established (no regulatory authorizations found) |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and no prediction was generated) |
| US Market Status | Not marketed (0 authorizations on record) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction is Available

This candidate's INN is a semicolon-delimited list of 30 distinct biological ingredients, including:

- **Multiple aeroallergens**: Ragweed (*Ambrosia artemisiifolia*), bermuda grass (*Cynodon dactylon*), birch (*Betula occidentalis*), oak (*Quercus kelloggii*), elm, ash, poplar, pine, juniper, and others
- **Food/environmental allergens**: English walnut, white mulberry, beef liver, alfalfa (*Medicago sativa*)
- **Skin-test controls**: HISTAMINE DIHYDROCHLORIDE (standard positive control) and CORTICOTROPIN (ACTH, used as a reference antigen in some panels)
- **Other botanicals**: Acacia, sage, cocklebur, Brazilian pepper tree pollen

The composition strongly suggests this is an **allergen immunotherapy diagnostic panel** or an **allergy skin-prick test kit**, rather than a single pharmaceutical entity suitable for drug repurposing analysis.

TxGNN operates on single-drug nodes mapped via DrugBank IDs. Because:
1. No DrugBank ID could be resolved for this multi-component mixture
2. The 30 ingredients do not map to a unified drug node in the knowledge graph
3. No approved indication exists as an anchor for repurposing search

…the pipeline produced no predictions. Without a defined original indication or a mappable drug node, repurposing analysis cannot proceed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate is a complex multi-component allergen mixture with no DrugBank mapping, no approved indication, and no TxGNN output. The standard repurposing pipeline cannot be applied to a product of this type in its current form.

**To proceed, the following is needed:**

- **Clarify the candidate identity**: Confirm whether the intent is to analyze a specific single active ingredient within this mixture (e.g., CORTICOTROPIN/ACTH as a standalone drug) rather than the mixture as a whole.
- **Resolve DrugBank mapping**: If CORTICOTROPIN is the target, query DrugBank with INN "corticotropin" (DB00836) to obtain a valid drug node for TxGNN.
- **Define original indication**: ACTH/corticotropin has established indications (infantile spasms, diagnostic adrenocortical insufficiency testing); these would serve as the repurposing anchor.
- **Re-run TxGNN** against the resolved single-drug node to obtain repurposing candidates.
- **Taiwan regulatory check**: Confirm whether any component of this mixture holds a separate TFDA authorization (e.g., corticotropin injection).

> **Note**: If the goal is allergen immunotherapy repurposing research, a different evidence framework (allergen-specific immunology databases, EAACI guidelines) should be used rather than the TxGNN small-molecule repurposing pipeline.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

